Immunovant, Inc.
NASDAQ:IMVTBiotechnology
+$0.69 today
- Market cap
- $6.86B
- Beta
- 0.79
- P/E (TTM)
- -14.3
- EPS (TTM)
- -$2.48
Volume 0.91M
Average 1.84M
IMVT EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Immunovant, Inc.NASDAQ: IMVT
EPS (Basic) · Q2 FY2027 · quarter ended Sep 2026
EPS (Basic) remains negative
Q2 FY2027 EPS (Basic) was -$0.47, compared with -$0.73 a year earlier. Trailing-twelve-month EPS (Basic) was -$2.56.
Context
- EPS (Basic) grew in size in 3 of the last 3 fiscal years.
- FY2026 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 9 analysts of -$2.65 (+4.2%) for the fiscal year ending Mar 2027, a step up from the -1.5% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$0.47+37.3% QoQ
- Last fiscal yearMar 2026
- -$2.77-1.5% YoY
- LTMSep 2026
- -$2.56+9.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +35.6% | -7.4% | -43.0 pp |
| 1 year | -1.5% | +4.2% | +5.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2026
- (2.77) USD
- Year-over-year change
- -1.5%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | (2.77) | -1.5% |
| FY2025 | 2025-03-31 | (2.73) | -45.2% |
| FY2024 | 2024-03-31 | (1.88) | -9.9% |
| FY2023 | 2023-03-31 | (1.71) | -19.6% |
| FY2022 | 2022-03-31 | (1.43) | — |
EPS (Basic) vs competitors
How IMVT compares with its peers on the latest reported figures
- IMVT's LTM Sep 2026 EPS (Basic) of -$2.56 is the 8th highest of the 11 companies compared; the peer median is -$1.04.
- Its year-over-year change of +9.9% is the 6th highest of 10, against a peer median of +23.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $2.68 | +154.3% | — | |
| LTM Sep 2026 | $0.74 | -75.8% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $0 | — | — |
| LTM Mar 2026 | -$0.56 | +59.7% | — | |
| LTM Mar 2026 | -$0.85 | +82.7% | — | |
| LTM Mar 2026 | -$1.22 | -3.4% | — | |
| LTM Mar 2026 | -$1.97 | +23.3% | — | |
| LTM Sep 2026 | -$2.56 | +9.9% | — | |
| LTM Mar 2026 | -$3.75 | -21.4% | — | |
| LTM Mar 2026 | -$5.98 | +39.0% | — | |
| LTM Mar 2026 | -$9.1 | -129.2% | — | |
| Peer median (excluding IMVT) | -$1.04 | +23.3% | — | |
Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 101.81M | 160.26M | 212.93M | 360.92M | 456.66M |
| Selling, General & Admin | 54.23M | 48.02M | 57.28M | 77.24M | 76.24M |
| Operating Expenses | 156.03M | 208.28M | 270.21M | 438.15M | 532.9M |
| Depreciation & Amortization | 126K | 193K | 231K | 377K | 409K |
| EBITDA | (156.69M) | (198.28M) | (258.54M) | (412.57M) | (504.98M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (156.03M) | (208.28M) | (270.21M) | (438.15M) | (532.9M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 7.58M | 24.95M | 24.73M | 25.33M |
| Interest Expense | 0 | 12.48M | 0 | 0 | 0 |
| Other Income / Expenses | (781K) | (2.68M) | 11.44M | 25.2M | 27.51M |
| Income Before Tax | (156.81M) | (210.95M) | (258.77M) | (412.95M) | (505.39M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (84K) | 9K | 567K | 891K | 215K |
| Net Income | (156.73M) | (210.96M) | (259.34M) | (413.84M) | (505.61M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) |
| EPS (Diluted) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) |
| Weighted Avg Shares | 109.68M | 123.08M | 138.1M | 151.57M | 182.42M |
| Weighted Avg Shares (Diluted) | 109.68M | 123.08M | 138.1M | 151.57M | 182.42M |
Immunovant, Inc.
NASDAQ:IMVT
Intrinsic Alpha fair value
Locked
Current Price
$33.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.